RGNX - Earnings call transcript Q4 2020

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon, and welcome to the REGENXBIO Fourth Quarter and Full Year 2020 Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will be given at that time.

As a reminder, this conference call is being recorded. I would now like to turn the call over to Mr. Officer Legal Chief Christmas, for REGENXBIO. Patrick

begin. may You

Patrick Christmas

call Dr. from call and available year, Officer. this by us ended anticipate, Good of reporting are be us Officer; include Steve and uncertainties XXXX. outlook press website is Medical guarantees released and year XX, and Securities that those performance report and of Chief forward-looking forward-looking and call December other may afternoon, and the intend the described call of are fourth our and our Financial at on XXXX, joining to the involve subject advised Officer Please otherwise. on may being Chief be full December Commission forecasted, March results comparable information sections the words release addition certain as statements will, and ended and account to file And and Any may, and for XX-Q, as XX, Form cause undertake X, afternoon, identified Analysis risks is information, Discussion expect, statements Management's thank on such www.regenxbio.com. product quarterly believe, the which that financial you Dr. statements date any the on operating no Today's of Officer; Chief today's plan, for SEC's conference of our the our and should, on our today. we Exchange meaning. financial factors on Any make REGENXBIO's quarter Pakola, Vit words events are only Danos, Ken provide Form and call, REGENXBIO conference Executive our are plans. XX-K Scientific With website. Chief new for of and These Risk forward-looking Olivier risks future differ on statements annual recorded REGENXBIO's update Mills, with or can Vasista, uncertainties. Earlier similar risk will regarding we report obligation President development on not this regulatory are financial and risks results actual such full XXXX. we this forward-looking to provided available The and webcast. to in results is REGENXBIO's These future this in Factors sections of

be may the to like positions addition, not In unaudited to financial differ provided Mills. results or Ken? the does financial any information call may company. I preliminary Actual project would materially. pro Ken of over results operating purport and turn forma now that is or to

Ken Mills

recent thanks our quarter and on platform, and everyone, safe us Patrick. expected pipeline, you, the of Olivier year and healthy. we'll everyone for for our hope fourth discuss results update Steve an financial full milestones and joined have to will provide future and provide the progress, that call, our Vit and expanding and XXXX. for a advancing Good Thank company. the NAV technology discuss recap is On us. I afternoon, conference today's staying joining

questions. goal our up therapy. towards strides potential of of We realizing for making curative we're the gene open will Throughout believe great already then I and XXXX, achieving call the in XXXX

affecting in to and partial evaluate highlights million vision an candidate to of our gene our first is achieve. program States. than This We therapy the call a cause touch a Wet on have X advanced internal leading Macular a program is Age-related more for disease people that to over ways. several just and Degeneration, the programs and exciting the loss, I'll retinal proud before broadened we're turning is United total Starting important team. pipeline pipeline milestone of our in important few that pivotal

gene trials largest the for a clinical the different targeted we gene trials new of super an potentially retinal disease. one-time data for to the retina. study, one-time origins our to patient, we therapy therapy space the novel disease. patients of these sub-retinal dosing of gene targeted eye. program parietal the a wet two we because therapeutic a can by the This Little These and therapy is delivery to RGX-XXX is approach. and generally order years trial. of programs evaluate setting, delivery believe X/X diseases delivery an to gene pathway with and the after Overall, to delivery of treatments been are in durable of that observed also evaluating using In genes our in retina administration, is settings similar XXXX, one-time therapy has be RGX-XXX retinopathy, a diabetic interrupt by for called of designed that the and have access The are therapy AMD, route delivery of established now providing any care. evaluating to initiated to effects we and is delivery we RGX-XXX where on Phase are allow that form all approach of routes ongoing are pivotal builds can patients program treatment from seen delivering non-surgical technique the three out in office population have administered that in work well-tolerated, RGX-XXX the gene provide like of to first Our we these to our using that of

biomarker directly And patient new treated replacement of treatment delivered and able includes data their that for is parts a the patients Our in nearly affects syndrome. prior a never gene the work in consistent our administration being fluid. is is We've patients of to of fluid, treatment cerebrospinal hunter every other into to data system. with enrolling evidence we're because cells therapy disease this brain This RGX-XXX neurodegeneration This organ. be to we administered exciting continued associated as the RGX-XXX trial. candidate that the reductions body. in enzyme by evidence encouraged trial. delivering is designed development in hunter to new single neurocognitive with shown nervous syndrome central to after also RGX-XXX providing treatment from that studied for us, by disease address in know may is cerebrospinal the care standard And it is were who to a patients

gene has excited but We to year. which a this of construct. announced based Muscular Olivier novel of our bring administration spearheading development is single Duchenne development microdystrophin this program a also recently RGX-XXX, program, potential on we're further treatment Dystrophy. for the of details, advanced the this been provide He'll forward therapy

and we're well-capitalized the milestones. program resources pipeline progress In our next to with achieve our potential, addition to plan

two continue our of We have as over recent advance this completed facility. and manufacturing build us support added and to $XXX transaction as well to million investment sheet, programs, platform, our out our enables to in commercial our that manufacturing to have ready balance

directly order an Friday, living advocates February before express the to of yesterday I enhance Finally, our teams me background, detailed to mission. Overall, it to sincere over needs as our days from work support have wish want diseases. With events our emerged year, taken special team, last going with REGENXBIO place appreciation, that, investigators, and most those to our Disease continue the recently. unwavering XX, On my XX, February that hard day, on especially and celebrated to of to to have update and leadership across turning in rare that of turn in dedicated a from employees, event that to moment I clinical partners the clinical the allowed team hear their messages hosted advance a to to opportunity take wonderful and active awareness support and more for programs. REGENXBIO we a what's importantly, worldwide call the on the many caregivers over acknowledge patient Rare in for communities I'll Steve this families, observed

Steve Pakola

Thanks, our the AMD, program, pivotal announced which treatment we Ken. I'll January. with of wet RGX-XXX in begin for

was pivotal total. of will expected in and program we two program End BLA pivotal to and clinical X design, well-controlled safety include patients enroll efficacy the is the potential filing a approximately we of meeting expect in to the to establishing focused Our on FDA evaluate primarily The XXXX. trials XXX which Phase believe support randomized, with RGX-XXX,

baseline Acuity begun our similarly enroll Phase from from trial pivotal The ranibizumab, we'll based change for versus elements year. ATMOSPHERE, Visual named using at escalation to design subretinal to the We have by Corrected RGX-XXX, dose non-inferiority which our be second is ATMOSPHERE. armed, intend expected in on dose XXXX, RGX-XXX of informed approximately to second-half trial patients already Best two to key administration. evaluate of in initiate first data enrolling expected ranibizumab, were designed the and X/Xa one patients in RGX-XXX. to the across of We is trial the trial ATMOSPHERE XXX

support a believe In our Manufacturing in cGMP, Commercial pivotal to addition, have Ready we program. Plans we path clear the

program AMD the material bridging manufacturing the to The of cGMP study pivotal produced cell Phase the expected long-term manufacturing RGX-XXX study. of presented our and our initiated trials. long-term support to using culture X/X pivotal XXXX. have from for to And study commercialization, of a wet is first-half and plan recently bridging additional in the suspension data treatment future trial initiate process. completion our we up follow the process, scalable incorporate of upon We We from existing

durable dose cohorts, continue RGX-XXX up effects have and earlier of to treatment years one across reported to to month, patients after well-tolerated this time continued we demonstrate RGX-XXX. As dosing generally all three be

patients encouraged We management are disease. and of of reductions including of stable injections, the for the in in by and dosed clinical treatment anti-VEGF patients durability vaccine which vision RGX-XXX, meaningful endpoints are very with their

in system is the and our patients, initial In targeting at Phase evaluating Phase delivery data second of X in Additionally, this in enrolling the and to completion are patients of enrollment we Cohort report genetic of data disease or we track remain portfolio diabetic for and the patients the to continued X positive injector now ongoing progress in XXXX. XXth from expansion of MPS in AAVIATE, on plan therapies portfolio, RGX-XXX, retinopathy with of quarter XXXX. report trial micro super recently Cohort third of of X January, in SCS Cohort rare XXXX. the AMD. hunter using data X Annual X our RGX-XXX RGX-XXX, pleased encouraging to complete and recent gene further syndrome. II We the advancements interim to interim enrollment of trial patients ALTITUDE, enrolling we and trial is treatment of from of parietal X, Cohort AAVIATE, our forward quarter the trial with diseases, from XXXX. in Phase evaluate announced we treatment X/X to of rare the Symposium our wet World look the of presented X for We expect with

activity well-tolerated in urine was administration dosing. RGX-XXX February, total levels to demonstrated in eight enzyme in following RGX-XXX. patients years and also enzyme plasma Notably, following Biomarkers activity, reported indicated evidence IXS RGX-XXX encouraging patients CNS of development, signals reductions replacement up IXS continued RGX-XXX, rapid therapy, in patients enzyme As in administration who demonstrated of showed and after dosed. the of one-time Patients two neurocognitive were to administration. naive two gag following urine of

spleen One begin the and in of We cohort and liver XXXX. of these of first to X higher enrolling patients expect dose a to in in had plan RGX-XXX evaluate significant quarter in Cohort reductions patients this volumes.

MPS of announced the RGX-XXX trial severe XXXX. age trial II to RGX-XXX in expected begin to include of previously plans also We Phase X/X patients a patients old. our over This is to the in dosing years pediatric second five first-half evaluate program expand with to

enrollment X/X of MPS has of treatment the addition, trial RGX-XXX Phase our In I. begun in for

an of other submit clinic. the of XXXX. disease We Our delivery advance plan RGX-XXX programs CLNX to disease the the interest towards first IND the rare treatment of in external continue for to quarter for

treatment Phase the foreign who a recently of We Olivier, discuss of also of trial the call RGX-XXX for RGX-XXX for XXXX. treatment of program X/X our to With IND disease the ocular I submit manifestations DMD. or in will over to expect an announced the CLNX equivalent turn Olivier? first-half will of that, for

Olivier Danos

DMD In in movements cells Steve. RGX-XXX, at the the the degenerate of muscle weak, and support death. of leading for of and breathing, many and premature of you, really dystrophin a gene Duchenne of working for of here muscle pursuit Without I'm which this and one-time we Dystrophy, required for and been proud loss independence, REGENXBIO becomes cardiomyopathy pathways. DMD. to in for job signaling Thank DMD eventually encodes in involved treatment dystrophin, caused development in program. the Muscular I've is this a January work structure by XXXX, years, announced protein gene, therapy mutations

equipped with muscle improvements muscle known integrity, back in improved the including a membrane C-terminal reduction patients resistance expression, clinical and AAVX genes from also this a and muscle. of the is reduce of the targeted Laboratory and based expression the the to Proof material increase to used been have incorporates process, key function. learning scale in RGX-XXX dystrophin and we Using plan expression promoter meaningful in to current DMD. clinical by of designed cells, efficiency, vector, and data capacity, occurring an muscle at in currently immunogenicity. muscle, University demonstrate development the novel content, a in of increases which will our in skeletal well-characterized concept is C-terminal muscle through to proteins Sciences. muscle of have which delivery in of gene can pathways Ken. that produced and with and only research. support uses cGMP leading naturally to conflict has studies strength coding is Dickson RGX-XXX key on manufacturing to optimization engineering we enabling muscle improvement mouse to commercial the model it recruitment specific cell to RGX-XXX. figure call RGX-XXX And culture in of expect numerous FDA in in I and the disrupting transgene, found other CPG IND and from pre-clinical fundamental of that, We're has extended material our to to we development RGX-XXX IND deliver micro the robust bolster domain. trials strength RGX-XXX suspension micro and design region signaling London, With dystrophin, which translational heart Our DMD, innovative George completing of believe histology vector studies cell already from REGENXBIO pioneering domain dystrophin improve of of over potential turn the NAV submit Ken? use and an the X,XXX-liter mid-XXXX. include

Ken Mills

updates to the clinical corporate that wanted just Muscular construction your Rockville, extend program for Maryland of Duchenne Steve, to new programs continues our as Dystrophy. Olivier's and about new here of and Olivier research the summary, in I Thanks, the to emergence and cGMP for facility add planned. our

allow We the expected new The to offices move suspension the fully in months, is culture new is to operational vectors production that up be our facility for to expect NAV facility our coming year. and the cGMP financials. production Vit We that to out into demands process. call a clinical to progress review match to platform scales set of With next expected X,XXX-liters, commercial using to and high deliver and see I'm entire at it's develop quality that, pipeline, far. the to NAV vectors going of over to facility our construction turn for so exciting a our scale would cell a

Vit Vasista

received the marketable of XXXX. attributable to used compared the revenue million of costs, in primarily gross The revenue to million services. and product cash securities third manufacturing trials a to associated for our were in million was XXXX, compared included increased million year expenses upon primarily administrative $XX.X net December ended to and XXXX. candidates. December the to XXXX, our was $XXX.X of offset of and XXXX, personnel increase as XX, million as XX, as million in were of million XXXX, $XX in of XXXX, compared a fee, Zolgensma The increased revenue, to and increase million XXXX, which was as and equivalents ended as XXXX. loss headcount XX, attributable ended of clinical in compared fees recognized an sales million other compared as and of for increase million the Thank $XX.X purchase XXXX, cumulative December Ken. $XX.X a royalty also the attributable milestone The Zolgensma. $XX.X to December XXXX. net XXXX. quarter achievement year personnel million attributable December ended $XXX.X $XXX.X $X ended compared to Revenues result for conducting expenses XXXX. was $XXX.X proceeds Research XX, advisory operating increase The cash, year result for The in $XXX the and totaling in of billion on development you, XX, year professional were expenses year Net as by to XX, activities, $XX.X December was in increased and for and million General the ended by $XXX.X headcount equipment year REGENXBIO from the the primarily with services, primarily December in for increase in for Zolgensma rights, property and net costs of monetization partially was lead royalty to cash the XX, with $XXX million, loss XXXX.

commissions of offering we capabilities, as the in of the offering December $XXX.X Including XXXX. an XX.X into approximately a second-half the public of our With January and share, $XX announced total additional a putting As and million completed offering public the XXXX, by from common operations, underwriters' XXXX, XX, of of as approximately XXX,XXX our forward XXXX, million and exercise, fire look per we REGENXBIO closing proceeds X.XXX December $XXX.X our to underwriting a clinical and common common the as to shares exercise of the shares XXXX. outstanding. were before product the the that, on the XXXX, the cash public its advancement January current fund as in REGENXBIO cash, stock completion public dumpster equivalents from Based $XXX.X in to well deducting in gross of million purchase full of XXXX, proceeds of offering gross XX, shares that underwritten including expect expenses. well our of we of option of XX as balance million, price the plan, the manufacturing other million, price. was our received of at stake operating option the securities discounts follow-on received On stock, internal offering at had marketable and to great candidates

to some final Now thoughts. Ken over for

Ken Mills

need. to we've look And entirety progress something therapies moved that that's to at the throughout and pipeline, internal XXXX, capabilities to has patients our The our been supporting our made for further us now closer bringing advance we of mission. in REGENXBIO to XXXX

I for the operator over think at this stage, turn to we'll call questions.

Operator

Thank question you, Presenters. [Operator Geoff of the comes Your from first line with instructions] Bank of Meacham America.

open. Your is line

Unidentified Analyst

taking design Hey for And Phase is of the study the guys. Alex on III XXX. Jeff, I on congrats question in one XXXX. for thanks on our This for question. have progress the

about in the the a study, we're I'd but two-week acuity of following the is submitted the there have as of would And assumptions, control the range cut guess on to change published expect you update? study? curious Eylea slightly off, I second expect in [ph] be for visual As thinking empowering better subretinal would follow-up the in size studies I your all, changed views Lucentis that, based maybe than to And Thanks. additional at arms? the appreciate III in a Phase know perform recent patients whether to

Ken Mills

Thanks, for the handle Steve, the I think arm. probably question control vision you powering Eylea Alex. Lucentis about can best

Steve Pakola

the such there's loading great in trials question. plethora of every other Yes, active data, monthly both Alex. drug dosing including Hey, as a control injection, dose. Eylea one where historical of including well after Lucentis of very this Great. well-controlled month space, It's benefits with as arms, Sure. development

powering. in expect into visual So, the thinking in of you we that good basically a control is first in terms that also look And treatment acuity of to there account those very of see variability your armed relevant of in to as for both from how in where to the the precedent powering non-inferiority of FDA, discussions terms terms answer with use that's what And of change of terms certainly took we there's question, for arm. and if those we think a baseline.

dosing take very what why is, Eylea. we this of and to to and you that's terms opportunity So, other in two dosing change, of treatment they're of every if see in use monthly study to monthly see expect similar terms And EA other arms. with Lucentis, to see you close month in you one frankly, pretty were, those excited with that what with interesting Eylea you the Lucentis. injection What's use with variability think

Operator

All right.

Matthew of Your next Stanley. Morgan question comes from Harrison the line with

Your is line open.

Unidentified Analyst

described. Kostas prior on One This one to in from do need on IND around Two improvements micro other in Thank dystrophin do differentiate clinic you you some program. give color what second mid-XXXX? the us versus expect the around Matthew. Hello, Can to you transgene filing do And improvement is, please in you. these everyone. you the investigational is that treatments? to for RGX-XXX questions the how is to

Ken Mills

Thanks, like sounds Olivier, great this Kostas. questions for you.

Olivier Danos

great Yes, you. Thank question.

we data before analyzing we our we're in preclinical file phase the the of So package have. final IND, that

We're also So have everything finalizing that, clinical that. from pretty of we together final all IND phases nice of done pasting a package. our But designing in it's apart far, a lot this the and in trial. much

the of molecule terms itself, micro the dystrophin. In

number functions a this key can shock a the or repairing membrane something it muscle dystrophin it channel, integrity adosynthase very is [ph], tested calcium micro including this dystrophin extra it slightly proteins, just bigger of we number there function dystrophy, after of can being C-terminal. other the is an way again, recovers that contraction. key out which than muscle is recruiting But for the work And actually has micro bone this were simple the the in having additional are preserves a If that will this distress. and is function a allows clinic, - dystrophin triggers other without absorber work proteins of the of the domain, because to So in which as - where of And which at the is dystrophin. as extra important the at the membrane. full domain domain of lack

translate force a exactly? several you treated it been that models, it ways does muscle being breaks contraction. the less strains more In submitted measure muscle That animal is has there how the stress of dystrophin actually down can is, that shows micro resilient. of are you that and to after So, with such

see we patient this the also this going Now, And play, file look the our to will coming be others. And this be that hope this at. clinic. resistance key something product is where design exactly sorry to in measuring is is way we our in when And we're that's - experience about clinical from eventually to be endpoint we the IND. is will into will discussed But this will fatigue eventually exercise. that fatigue after of eventually differentiating amount what

In to going Although, not compare directly. we're to going trial, not we're do that. this

I'm the come about the development definitely in a So products. later that talking will point of

Ken Mills

Thanks, Olivier.

Operator

line Your UBS. of Rajavelu next Esther from question the comes with

Your line open. is

Esther Rajavelu

guys. taking my for Hey, Thanks question.

Cohort First OCT. looks X? angiogenesis not between as a X had about follow talk up X but data. Cohort BCBA better OCT and It distinctions Cohort like to the the you BCBA, Can

to And that yet. then, So understand OCT from X the data available to not confirm is I'm I Cohort trying that. three-year also wanted

Steve Pakola

here. take can Steve I that Yes, one,

to So, X.X-year follow-up yes, in for data well for latest three-year terms we MC-V, the as at as present angiogenesis, we Cohort X. the of were excited had results

anatomy acuity but raised you thickness retinal response both terms how central changes. at in a also visual As of of good look point we

as significant of CRT, speak. arm, aspects little less you there levels this drier example, so in be an where to slightly baseline ability if of you in off ceiling trials basically for decrease, can the per retina, size in you study can is of this patients effect, XX to different six a have have One start a where a with have

in terms of the relatively improvement the a explains stable. example, distinction in acuity, central that thickness believe see what between you that's So, visual stays we almost for what fact anatomy, three-line the see retinal the we CX, in while

aspect, typical what be out having with peak injections you anatomy. you'd need be outcomes better may larger possibility trough anticipate to than trials. traditional repeat really that the visual may I into translate without stable and on other The have the But there borne variability bolus think that based would that in anatomy,

the off those those CRT levels, be central stable in thickness levels even see The from come And terms that's the be that of levels, over excited started retinal the of doses decreased continued been other data all down that with CX we seen to them to a signals higher we why cohorts with really range baseline looking burden. treatment efficacy upward of time, we've in did with at and of were at. with continue dramatic excited continue the reduction levels, maturation and we've

Operator

you. Thank

comes next line with Barclays. Gena Your Wang from question of the

Your line is open.

Unidentified Analyst

David Thanks on as I Hi, XXXX this Gena. congrats in is my for taking on for well. questions. And progress your to want

- gene So, subretinal a therapy couple on of questions injections. on VEG RGX-XXX

Phase the is you regarding trial, the question your First III us could trial design? for remind retreatment criteria Phase III

Steve Pakola

Sure.

fashion a based retinal done board. on which have controlled mass do criteria is central a felt by center. mass was to reading the And a standardized this also central which is retreatment measures, change, thickness specifically fashion, and it best we Phase and objective acuity in across important our visual III also So, in going done program, into corrected to anatomy

to the those terms are or anatomy, compared criteria fit to the of in a some across compared of other two the visits, to concept an what very the the a the at best to the our prior in measures retinal of XXX microns of at a The decrease of the there, pivotal attempting prior increase visit. XX somewhat at least for of in difference CRT attempt and that are out those XX retreatment. average worsening level treatment letters of visit. terms to prior specific, five of worsening our best that one-time are And study compared here potentially that prior effect. being the obviate option retreatment or average microns this for So, durability of be visual criteria or mix and programs you see prior to two a a visits, of is treatment some acuity similar of increase And compared letters looking worsening need to the thickness to precedents other that and

Operator

Foroohar comes Instructions] [Operator the Mani next line question from Your Leerink. of with SVB

is line open. Your

Unidentified Analyst

Rick good Hey, our is question. line taking This Thanks for afternoon. for on Mani.

on inform wondering any program. We Since surreptitious program. focused you the gene RGX-XXX, a question my So, update comment clinical potential learnings from if could the DMD on from there first were announced therapy you dose was of readout of trial, if selection, competitor. goals able And for trial it the was escalation. as your help patient of to initial upcoming design selection for were aspect clinical your endpoints such any

Ken Mills

think well. advancement design someone by platform comment study, available from that's on described well into also we're help robust but not a not manufacturing have meaningful proprietary be using that that in preparing that really Yes, differentiation we of this data compared program, elements to a to gone Rick. along only using for demonstrated course, domain. a obviously dystrophin already for things work class, to of preclinical been a as Olivier important what as wouldn't else's trial to potentially to that have illustrate, we will would construct is of And as We're the micro has going interpret the way program us as C-terminals novel

top-line going there from is not that someone learn of running. a that study So, is else much sort results we're from

Operator

you. Thank

with next RBC. comes the Issi Luca question from of line Your

Your line is open.

Lisa Walter

Walter Oh, for my is question. taking Lisa great. Thanks Luca. This for on

highest considerations the Phase Can from the some are color Cohort starting And like you Thanks. on switching ask subretinal you in of suprachoroidal. are that for that dose is provide also X. why broadly, super any maybe doubling key also your suprachoroidal case? more tested the wanted the about dosing parietal to program. at dose what that the when ever there trial you It subretinal to X Just and are looks for

Steve Pakola

Yes.

program. really this the that advantage from had So we subretinal all takes our learnings of

got had we you'll of So, clear new the there recall, full dose progressively plateau up we low Lisa, where a is with This dose anything, once our route signal we and went benefit ranging super administration. we perspective, onward. a a as from didn't level a with saw we to of see where three then more started

close administration very to achieves getting particularly is tissue RPE However, think other of of the that compared note the goal of to target [Indiscernible]. I still the like it routes photoreceptors, the to infusae in important the it

both had range from level with five our include either gave also pharmacology our GLP subretinal, very studies start a for with were as full from the start we do tolerability where well studies. package, we we we a go We that our as preclinical were subretinal. be So that to from pleased to package, the start and of our position standpoint. suprachoroidal able safety that not And prophylactic to chose that pleased opportunity equipoise with doses us initial since design steroids of in had we good dose of and delivery to

potential the with same factor signal. with delivery to dose subretinal with that take to where think I aspect not of start. start and the exact same of think just a AAV safety but and exact only tolerability, prior good of a question. always I yes, thinking experience So, when And key the benefit dosing of you lot a starting a you're evaluate, transgene, It's advantage had to we

Operator

ahead, this There I'd you. questions the like Ken Go over turn at no to for back sir. call Thank closing remarks. to are further time.

Ken Mills

great thanks, for have updates throughout you providing much. And joining year everyone, and us today. further forward night. Thank the We and very a to look soon

Operator

this today's a gentlemen, day. you participation Thank and Ladies your and concludes have wonderful for conference.

may You all disconnect.

REGENXBIO (RGNX) 2 Mar 212020 Q4 Earnings call transcript